[üá∑üá∫ –†—É—Å—Å–∫–∞—è –≤–µ—Ä—Å–∏—è](README.ru.md) | [üá¨üáß English version](README.md)

---

# Ozon Silk Road: Expansion into Uzbekistan Pharma Market

**University project**: Fundamentals of Business Analysis (Central University)  
**Team**: Nikita Tolmachev, Artem Sukhanov, Egor Starikov  
**Timeline**: December 2024

---

## Challenge

Develop a comprehensive market entry strategy for Ozon Pharm's expansion into Uzbekistan's pharmaceutical market, covering strategy, product, operations, marketing, unit economics, and financial projections.

---

## Solution Overview

Our team designed a full-scale expansion plan for entering Uzbekistan's rapidly growing pharma market through generic drug distribution.

### Market Opportunity

- **TAM**: $1.9B (2023)
- **Market growth**: 15%+ annually
- **Import share**: 75% of total market
- **Target market share**: 1-3% initially

### Strategic Approach

**Entry strategy**: Partnership with local distributors (minimal capex, faster time-to-market)

**Product positioning**: High-quality generic drugs at competitive prices (15-18% markup vs. Russian retail)

**Competitive advantages**:
- Largest generic portfolio in Russia (378M+ packages/year production capacity)
- Strategic location (Samara production facilities enable easy logistics)
- Trusted Russian brand recognition in CIS markets

### Business Model

**Distribution channels**:
- Major pharmacy chains (Grandpharm, Shohfarm, OXYmed)
- Online platforms (Apteka.uz, Uzum, Wildberries Uzbekistan)
- Hospitals and clinics
- Direct B2B partnerships with distributors

**Pricing strategy**: Competitor-based + value-based hybrid, targeting middle-income segments

---

## Key Results

### Unit Economics
- **Average transaction**: ‚ÇΩ167.2 (20,398 UZS)
- **CAC**: ‚ÇΩ11.3 (4.7% of revenue)
- **Operating costs**: ‚ÇΩ46.5 (12.8% of revenue)
- **Profit per unit**: ‚ÇΩ21.8 (14% margin)

Industry benchmark: 13.4% average margin ‚Äî **our model exceeds industry standard by 0.6pp**

### Financial Projections (Year 1)
- **Revenue**: ‚ÇΩ3.22B
- **Operating expenses**: ‚ÇΩ2.80B
- **Net profit**: ‚ÇΩ420M annually
- **Initial investment**: ‚ÇΩ253M (warehouse build-out scenario)
- **Payback period**: 7-8 months

---

## My Contribution

- **Market research**: analyzed Uzbekistan pharma market dynamics (TAM/SAM/SOM sizing, growth drivers, regulatory landscape)
- **Competitive analysis**: benchmarked Russian competitors (Materia Medica, Valenta, Nizhpharm) and pricing strategies; conducted Porter's 5 Forces assessment
- **Unit economics modeling**: built financial model in Excel with revenue/cost structure, calculated unit-level profitability, and validated against industry benchmarks
- **Strategic frameworks**: contributed to 3C analysis, SWOT, and market entry strategy selection (partnership vs. M&A vs. in-house)

---

## Frameworks & Methods

### Strategy
- 3C Analysis (Company, Customers, Competition)
- PESTEL (macro environment)
- Porter's 5 Forces
- SWOT

### Pricing
- Competitor-based pricing
- Value-based pricing
- Cost-based pricing

### Marketing
- Customer Journey Map (CJM)
- Marketing Mix (4P)
- Channel effectiveness analysis (CAC, conversion rates)

### Finance
- NPV, IRR, payback period
- Unit economics (LTV, CAC, contribution margin)
- Sensitivity analysis

---

## Tech Stack & Tools

- **Financial modeling**: MS Excel (DCF, unit economics, P&L projections)
- **Presentation**: MS PowerPoint
- **Research**: Open-source market data, regulatory databases, competitor benchmarking

---

## Documentation

- [Final presentation](/ozon_presentation.pdf) ‚Äî full strategy deck with analysis and recommendations
- [Financial model](/ozon_financials.xlsx) ‚Äî unit economics and investment calculations

---

## About the Project

This project was completed as part of the "Fundamentals of Business Analysis" course at Central University. Teams were tasked with developing real-world expansion strategies for companies entering new markets, applying rigorous analytical frameworks across strategy, operations, marketing, and finance.

